[Learning with COVID-19: what about anticoagulation?]
Identifieur interne : 000052 ( Main/Exploration ); précédent : 000051; suivant : 000053[Learning with COVID-19: what about anticoagulation?]
Auteurs : E. Álvarez-Rodríguez ; R. González González ; R. Torres-Gárate ; P. L Pez-Riquelme ; I. González Martil ; V. Abad Cu AdoSource :
- Anales del sistema sanitario de Navarra [ 1137-6627 ] ; 2020.
Descripteurs français
- KwdFr :
- Abdomen (MeSH), Acénocoumarol (effets indésirables), Acénocoumarol (usage thérapeutique), Anticoagulants (effets indésirables), Anticoagulants (usage thérapeutique), Betacoronavirus (MeSH), Femelle (MeSH), Humains (MeSH), Hématome (diagnostic), Hématome (induit chimiquement), Héparine bas poids moléculaire (effets indésirables), Héparine bas poids moléculaire (usage thérapeutique), Infections à coronavirus (complications), Pandémies (MeSH), Pneumopathie virale (complications), Rivaroxaban (effets indésirables), Rivaroxaban (usage thérapeutique), Sujet âgé de 80 ans ou plus (MeSH), Thromboembolisme veineux (prévention et contrôle), Thromboembolisme veineux (traitement médicamenteux), Thromboembolisme veineux (virologie).
- MESH :
- diagnostic : Hématome.
- effets indésirables : Acénocoumarol, Anticoagulants, Héparine bas poids moléculaire, Infections à coronavirus, Pneumopathie virale, Rivaroxaban.
- induit chimiquement : Hématome.
- prévention et contrôle : Thromboembolisme veineux.
- traitement médicamenteux : Thromboembolisme veineux.
- usage thérapeutique : Acénocoumarol, Anticoagulants, Héparine bas poids moléculaire, Rivaroxaban.
- virologie : Thromboembolisme veineux.
- Abdomen, Betacoronavirus, Femelle, Humains, Pandémies, Sujet âgé de 80 ans ou plus.
English descriptors
- KwdEn :
- Abdomen (MeSH), Acenocoumarol (adverse effects), Acenocoumarol (therapeutic use), Aged, 80 and over (MeSH), Anticoagulants (adverse effects), Anticoagulants (therapeutic use), Betacoronavirus (MeSH), Coronavirus Infections (complications), Female (MeSH), Hematoma (chemically induced), Hematoma (diagnosis), Heparin, Low-Molecular-Weight (adverse effects), Heparin, Low-Molecular-Weight (therapeutic use), Humans (MeSH), Pandemics (MeSH), Pneumonia, Viral (complications), Rivaroxaban (adverse effects), Rivaroxaban (therapeutic use), Venous Thromboembolism (drug therapy), Venous Thromboembolism (prevention & control), Venous Thromboembolism (virology).
- MESH :
- chemical , adverse effects : Acenocoumarol, Anticoagulants, Heparin, Low-Molecular-Weight, Rivaroxaban.
- chemical , therapeutic use : Acenocoumarol, Anticoagulants, Heparin, Low-Molecular-Weight, Rivaroxaban.
- chemically induced : Hematoma.
- complications : Coronavirus Infections, Pneumonia, Viral.
- diagnosis : Hematoma.
- drug therapy : Venous Thromboembolism.
- prevention & control : Venous Thromboembolism.
- virology : Venous Thromboembolism.
- Abdomen, Aged, 80 and over, Betacoronavirus, Female, Humans, Pandemics.
Abstract
Infection caused by SARS-CoV-2 (COVID-19) is associated with an increased risk of thromboembolic disease. So-me authors recommend anticoagulation at therapeutic doses for, at least, the most severely ill patients; this practice is not free of risks, which is why only thromboembolic prophylaxis is recommended by other consensuses. In the case of previously anticoagulated patients, changing the oral anticoagulant for a low molecular weight heparin (LMWH) is generally recommended. We present the cases of two patients admitted due to COVID-19, without serious clinical data, in whom anticoagulation (acenocoumarol and rivaroxaban, respectively) was replaced by LMWH at therapeutic doses, both presenting abdominal bleeding. This type of bleeding is an infrequent complication in anticoagulated patients, but the concurrence of two cases in a short period of time in the context of the COVID-19 pandemic leads us to consider that there is not yet any clear evidence on therapeutic anticoagulation in SARS-CoV-2 infection.
DOI: 10.23938/ASSN.0884
PubMed: 32865189
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Learning with COVID-19: what about anticoagulation?]</title><author><name sortKey="Alvarez Rodriguez, E" sort="Alvarez Rodriguez, E" uniqKey="Alvarez Rodriguez E" first="E" last="Álvarez-Rodríguez">E. Álvarez-Rodríguez</name><affiliation><nlm:affiliation>Servicio de Urgencias. Hospital Universitario Severo Ochoa. Leganés, Madrid.. diabetes@portalsemes.org.</nlm:affiliation><wicri:noCountry code="subField">Madrid..</wicri:noCountry></affiliation></author><author><name sortKey="Gonzalez Gonzalez, R" sort="Gonzalez Gonzalez, R" uniqKey="Gonzalez Gonzalez R" first="R" last="González González">R. González González</name></author><author><name sortKey="Torres Garate, R" sort="Torres Garate, R" uniqKey="Torres Garate R" first="R" last="Torres-Gárate">R. Torres-Gárate</name></author><author><name sortKey="L Pez Riquelme, P" sort="L Pez Riquelme, P" uniqKey="L Pez Riquelme P" first="P" last="L Pez-Riquelme">P. L Pez-Riquelme</name></author><author><name sortKey="Gonzalez Martil, I" sort="Gonzalez Martil, I" uniqKey="Gonzalez Martil I" first="I" last="González Martil">I. González Martil</name></author><author><name sortKey="Abad Cu Ado, V" sort="Abad Cu Ado, V" uniqKey="Abad Cu Ado V" first="V" last="Abad Cu Ado">V. Abad Cu Ado</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32865189</idno><idno type="pmid">32865189</idno><idno type="doi">10.23938/ASSN.0884</idno><idno type="wicri:Area/Main/Corpus">000422</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000422</idno><idno type="wicri:Area/Main/Curation">000422</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000422</idno><idno type="wicri:Area/Main/Exploration">000422</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Learning with COVID-19: what about anticoagulation?]</title><author><name sortKey="Alvarez Rodriguez, E" sort="Alvarez Rodriguez, E" uniqKey="Alvarez Rodriguez E" first="E" last="Álvarez-Rodríguez">E. Álvarez-Rodríguez</name><affiliation><nlm:affiliation>Servicio de Urgencias. Hospital Universitario Severo Ochoa. Leganés, Madrid.. diabetes@portalsemes.org.</nlm:affiliation><wicri:noCountry code="subField">Madrid..</wicri:noCountry></affiliation></author><author><name sortKey="Gonzalez Gonzalez, R" sort="Gonzalez Gonzalez, R" uniqKey="Gonzalez Gonzalez R" first="R" last="González González">R. González González</name></author><author><name sortKey="Torres Garate, R" sort="Torres Garate, R" uniqKey="Torres Garate R" first="R" last="Torres-Gárate">R. Torres-Gárate</name></author><author><name sortKey="L Pez Riquelme, P" sort="L Pez Riquelme, P" uniqKey="L Pez Riquelme P" first="P" last="L Pez-Riquelme">P. L Pez-Riquelme</name></author><author><name sortKey="Gonzalez Martil, I" sort="Gonzalez Martil, I" uniqKey="Gonzalez Martil I" first="I" last="González Martil">I. González Martil</name></author><author><name sortKey="Abad Cu Ado, V" sort="Abad Cu Ado, V" uniqKey="Abad Cu Ado V" first="V" last="Abad Cu Ado">V. Abad Cu Ado</name></author></analytic><series><title level="j">Anales del sistema sanitario de Navarra</title><idno type="ISSN">1137-6627</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Abdomen (MeSH)</term><term>Acenocoumarol (adverse effects)</term><term>Acenocoumarol (therapeutic use)</term><term>Aged, 80 and over (MeSH)</term><term>Anticoagulants (adverse effects)</term><term>Anticoagulants (therapeutic use)</term><term>Betacoronavirus (MeSH)</term><term>Coronavirus Infections (complications)</term><term>Female (MeSH)</term><term>Hematoma (chemically induced)</term><term>Hematoma (diagnosis)</term><term>Heparin, Low-Molecular-Weight (adverse effects)</term><term>Heparin, Low-Molecular-Weight (therapeutic use)</term><term>Humans (MeSH)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (complications)</term><term>Rivaroxaban (adverse effects)</term><term>Rivaroxaban (therapeutic use)</term><term>Venous Thromboembolism (drug therapy)</term><term>Venous Thromboembolism (prevention & control)</term><term>Venous Thromboembolism (virology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Abdomen (MeSH)</term><term>Acénocoumarol (effets indésirables)</term><term>Acénocoumarol (usage thérapeutique)</term><term>Anticoagulants (effets indésirables)</term><term>Anticoagulants (usage thérapeutique)</term><term>Betacoronavirus (MeSH)</term><term>Femelle (MeSH)</term><term>Humains (MeSH)</term><term>Hématome (diagnostic)</term><term>Hématome (induit chimiquement)</term><term>Héparine bas poids moléculaire (effets indésirables)</term><term>Héparine bas poids moléculaire (usage thérapeutique)</term><term>Infections à coronavirus (complications)</term><term>Pandémies (MeSH)</term><term>Pneumopathie virale (complications)</term><term>Rivaroxaban (effets indésirables)</term><term>Rivaroxaban (usage thérapeutique)</term><term>Sujet âgé de 80 ans ou plus (MeSH)</term><term>Thromboembolisme veineux (prévention et contrôle)</term><term>Thromboembolisme veineux (traitement médicamenteux)</term><term>Thromboembolisme veineux (virologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Acenocoumarol</term><term>Anticoagulants</term><term>Heparin, Low-Molecular-Weight</term><term>Rivaroxaban</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Acenocoumarol</term><term>Anticoagulants</term><term>Heparin, Low-Molecular-Weight</term><term>Rivaroxaban</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Hematoma</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Hematoma</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Hématome</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Venous Thromboembolism</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Acénocoumarol</term><term>Anticoagulants</term><term>Héparine bas poids moléculaire</term><term>Infections à coronavirus</term><term>Pneumopathie virale</term><term>Rivaroxaban</term></keywords><keywords scheme="MESH" qualifier="induit chimiquement" xml:lang="fr"><term>Hématome</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Venous Thromboembolism</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Thromboembolisme veineux</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Thromboembolisme veineux</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Acénocoumarol</term><term>Anticoagulants</term><term>Héparine bas poids moléculaire</term><term>Rivaroxaban</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Thromboembolisme veineux</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Venous Thromboembolism</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Abdomen</term><term>Aged, 80 and over</term><term>Betacoronavirus</term><term>Female</term><term>Humans</term><term>Pandemics</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Abdomen</term><term>Betacoronavirus</term><term>Femelle</term><term>Humains</term><term>Pandémies</term><term>Sujet âgé de 80 ans ou plus</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Infection caused by SARS-CoV-2 (COVID-19) is associated with an increased risk of thromboembolic disease. So-me authors recommend anticoagulation at therapeutic doses for, at least, the most severely ill patients; this practice is not free of risks, which is why only thromboembolic prophylaxis is recommended by other consensuses. In the case of previously anticoagulated patients, changing the oral anticoagulant for a low molecular weight heparin (LMWH) is generally recommended. We present the cases of two patients admitted due to COVID-19, without serious clinical data, in whom anticoagulation (acenocoumarol and rivaroxaban, respectively) was replaced by LMWH at therapeutic doses, both presenting abdominal bleeding. This type of bleeding is an infrequent complication in anticoagulated patients, but the concurrence of two cases in a short period of time in the context of the COVID-19 pandemic leads us to consider that there is not yet any clear evidence on therapeutic anticoagulation in SARS-CoV-2 infection.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32865189</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>05</Day></DateCompleted><DateRevised><Year>2020</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">1137-6627</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>2</Issue><PubDate><Year>2020</Year><Month>Aug</Month><Day>31</Day></PubDate></JournalIssue><Title>Anales del sistema sanitario de Navarra</Title><ISOAbbreviation>An Sist Sanit Navar</ISOAbbreviation></Journal><ArticleTitle>[Learning with COVID-19: what about anticoagulation?]</ArticleTitle><Pagination><MedlinePgn>251-254</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.23938/ASSN.0884</ELocationID><Abstract><AbstractText>Infection caused by SARS-CoV-2 (COVID-19) is associated with an increased risk of thromboembolic disease. So-me authors recommend anticoagulation at therapeutic doses for, at least, the most severely ill patients; this practice is not free of risks, which is why only thromboembolic prophylaxis is recommended by other consensuses. In the case of previously anticoagulated patients, changing the oral anticoagulant for a low molecular weight heparin (LMWH) is generally recommended. We present the cases of two patients admitted due to COVID-19, without serious clinical data, in whom anticoagulation (acenocoumarol and rivaroxaban, respectively) was replaced by LMWH at therapeutic doses, both presenting abdominal bleeding. This type of bleeding is an infrequent complication in anticoagulated patients, but the concurrence of two cases in a short period of time in the context of the COVID-19 pandemic leads us to consider that there is not yet any clear evidence on therapeutic anticoagulation in SARS-CoV-2 infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Álvarez-Rodríguez</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Servicio de Urgencias. Hospital Universitario Severo Ochoa. Leganés, Madrid.. diabetes@portalsemes.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>González González</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Torres-Gárate</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>López-Riquelme</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>González Martil</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Abad Cuñado</LastName><ForeName>V</ForeName><Initials>V</Initials></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>An Sist Sanit Navar</MedlineTA><NlmUniqueID>9710381</NlmUniqueID><ISSNLinking>1137-6627</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006495">Heparin, Low-Molecular-Weight</NameOfSubstance></Chemical><Chemical><RegistryNumber>9NDF7JZ4M3</RegistryNumber><NameOfSubstance UI="D000069552">Rivaroxaban</NameOfSubstance></Chemical><Chemical><RegistryNumber>I6WP63U32H</RegistryNumber><NameOfSubstance UI="D000074">Acenocoumarol</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName><SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000005" MajorTopicYN="N">Abdomen</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000074" MajorTopicYN="N">Acenocoumarol</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006406" MajorTopicYN="N">Hematoma</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006495" MajorTopicYN="N">Heparin, Low-Molecular-Weight</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069552" MajorTopicYN="N">Rivaroxaban</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="N">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32865189</ArticleId><ArticleId IdType="doi">10.23938/ASSN.0884</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list></list><tree><noCountry><name sortKey="Abad Cu Ado, V" sort="Abad Cu Ado, V" uniqKey="Abad Cu Ado V" first="V" last="Abad Cu Ado">V. Abad Cu Ado</name><name sortKey="Alvarez Rodriguez, E" sort="Alvarez Rodriguez, E" uniqKey="Alvarez Rodriguez E" first="E" last="Álvarez-Rodríguez">E. Álvarez-Rodríguez</name><name sortKey="Gonzalez Gonzalez, R" sort="Gonzalez Gonzalez, R" uniqKey="Gonzalez Gonzalez R" first="R" last="González González">R. González González</name><name sortKey="Gonzalez Martil, I" sort="Gonzalez Martil, I" uniqKey="Gonzalez Martil I" first="I" last="González Martil">I. González Martil</name><name sortKey="L Pez Riquelme, P" sort="L Pez Riquelme, P" uniqKey="L Pez Riquelme P" first="P" last="L Pez-Riquelme">P. L Pez-Riquelme</name><name sortKey="Torres Garate, R" sort="Torres Garate, R" uniqKey="Torres Garate R" first="R" last="Torres-Gárate">R. Torres-Gárate</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidSeniorV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000052 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000052 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidSeniorV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32865189
|texte= [Learning with COVID-19: what about anticoagulation?]
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32865189" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidSeniorV1
| This area was generated with Dilib version V0.6.37. |  |